Gilgamesh Pharmaceuticals Analysis: $39M Raised
What is Gilgamesh Pharmaceuticals?
Gilgamesh Pharma develops novel chemical entities for psychiatric and neurological disorders. Its pipeline includes fast-acting depression candidates, a safer ibogaine analog, and muscarinic receptor agonists for schizophrenia. The company has reported clinical-stage progress, including Phase 2 results and one asset acquired by AbbVie.
Location
113 University Pl, New York, New York 10003, United States
Employees
11-50
Founded
2019
Revenue
$5M
Product Features & Capabilities
- NMDAR Antagonist: orally bioavailable, rapid-acting, fewer dissociative effects, for depression
- 5-HT2AR Agonists: rapid acting, optimized duration of effect, improved cardiac safety profile, for depression and other indications
- Neuroplastogens: rapid acting, orally bioavailable, non-hallucinogenic, for depression and anxiety
- Safer Ibogaine Analogs: rapid and sustained efficacy, improved cardiac safety profile, for opioid use disorder and other indications.
How much Gilgamesh Pharmaceuticals raised
Series B - $39,000,000
December 15, 2022Lead Investor: Not specified in the sources.
Who are the founders of Gilgamesh Pharmaceuticals
Market Focus
Gilgamesh Pharmaceuticals primarily focuses on the biotechnology industry, specifically in the clinical-stage neuroscience sector, developing innovative therapies for psychiatric diseases.
Investors
- National Institute on Drug Abuse (NIDA)
- 10X Capital
- Alumni Ventures
- Ayuh Ventures
- PsyMed Ventures
- Prime Movers Lab
- Palo Santo
- Negev Capital
- Route 66 Ventures
- JLS Fund
- Satori
- Gron Ventures
- Noetic Psychedelic Fund
Business Model
Collaborations and funding from partnerships drive revenue through licensing and clinical trials.
Competitors Overview
Gilgamesh Pharmaceuticals operates in the neuroscience biotech sector, focusing on innovative treatments for psychiatric diseases. Its main competitors include:
-
ATAI Life Sciences: A clinical-stage biopharmaceutical company dedicated to developing effective mental health treatments. ATAI emphasizes a robust pipeline of compounds targeting various psychiatric conditions, including anxiety, depression, and schizophrenia. Their approach includes precision psychiatry, which aims to tailor treatments to individual patient needs.
-
COMPASS Pathways: Known for its work in developing psilocybin therapy for treatment-resistant depression, COMPASS Pathways has a strong focus on evidence-based therapeutics. They have a diverse pipeline and are recognized for their innovative approaches to mental health treatment, including partnerships and collaborations to enhance their research capabilities.
-
Beckley Psytech: This company is focused on developing rapid-acting and accessible medicines for mental health conditions. They are pioneering next-generation treatments that aim to address the underlying causes of psychiatric disorders rather than just managing symptoms.
Notable differences and advantages:
- ATAI Life Sciences has a broad range of compounds and a focus on precision medicine, which may provide tailored treatment options.
- COMPASS Pathways is particularly noted for its pioneering work with psilocybin, which could offer unique therapeutic benefits compared to traditional treatments.
- Beckley Psytech emphasizes rapid-acting therapies, which align with Gilgamesh's focus on durable treatments, but they may have different methodologies or compounds in development.
See something that needs updating? Suggest edits to this profile.